Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab
and how well they work together for treating patients with mantle cell lymphoma that has come
back after a period of improvement (relapsed) or that has not responded to previous treatment
(refractory). Acalabrutinib is in a class of medications called kinase inhibitors. It blocks
a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such
as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and
spreading. A monoclonal antibody is a type of protein that can bind to certain targets in the
body, such as molecules that cause the body to make an immune response (antigens).
Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune
system attack the cancer, and may interfere with the ability of cancer cells to grow and
spread. Glofitamab is a class of medications called bispecific antibodies. Bispecific
antibodies are designed to simultaneously bind to T cells and cancer cell antigens, leading
to T-cell activation, proliferation, and cancer cell death. Giving acalabrutinib,
obinutuzumab, and glofitamab together may be a safe and effective treatment for patients with
relapsed or refractory mantle cell lymphoma.